Literature DB >> 19797782

Cardiopulmonary stress testing in patients with pulmonary artery hypertension.

Ross Arena, Carl J Lavie.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19797782      PMCID： PMC2755813          DOI： 10.1016/S0025-6196(11)60510-7

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  9 in total

1.  Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2).

Authors:  D P Francis; W Shamim; L C Davies; M F Piepoli; P Ponikowski; S D Anker; A J Coats
Journal:  Eur Heart J       Date:  2000-01       Impact factor: 29.983

2.  Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction: recommendations for performance and interpretation. Part I: definition of cardiopulmonary exercise testing parameters for appropriate use in chronic heart failure.

Authors:  Massimo F Piepoli; Ugo Corrà; Pier Giuseppe Agostoni; Romualdo Belardinelli; Alain Cohen-Solal; Rainer Hambrecht; Luc Vanhees
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2006-04

3.  Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction: recommendations for performance and interpretation Part II: How to perform cardiopulmonary exercise testing in chronic heart failure.

Authors:  Massimo F Piepoli; Ugo Corrà; Pier Giuseppe Agostoni; Romualdo Belardinelli; Alain Cohen-Solal; Rainer Hambrecht; Luc Vanhees
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2006-06

Review 4.  The clinical and research applications of aerobic capacity and ventilatory efficiency in heart failure: an evidence-based review.

Authors:  Ross Arena; Jonathan Myers; Marco Guazzi
Journal:  Heart Fail Rev       Date:  2007-11-07       Impact factor: 4.214

5.  Assessment of functional capacity in clinical and research settings: a scientific statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing.

Authors:  Ross Arena; Jonathan Myers; Mark A Williams; Martha Gulati; Paul Kligfield; Gary J Balady; Eileen Collins; Gerald Fletcher
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

6.  Recommendations for clinical exercise laboratories: a scientific statement from the american heart association.

Authors:  Jonathan Myers; Ross Arena; Barry Franklin; Ileana Pina; William E Kraus; Kyle McInnis; Gary J Balady
Journal:  Circulation       Date:  2009-06-01       Impact factor: 29.690

7.  Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review.

Authors:  Ross Arena; Carl J Lavie; Richard V Milani; Jonathan Myers; Marco Guazzi
Journal:  J Heart Lung Transplant       Date:  2009-12-06       Impact factor: 10.247

8.  Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction: recommendations for performance and interpretation Part III: Interpretation of cardiopulmonary exercise testing in chronic heart failure and future applications.

Authors: 
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2006-08

9.  Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension.

Authors:  Darren B Taichman; Michael D McGoon; Michael O Harhay; Chris Archer-Chicko; Jeffrey S Sager; Meena Murugappan; Murali M Chakinali; Harold I Palevsky; Robert Gallop
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616
  9 in total
  1 in total

1.  Comprehensive Exercise Capacity and Quality of Life Assessments Predict Mortality in Patients with Pulmonary Arterial Hypertension.

Authors:  Yi-Jen Chen; Hung-Pin Tu; Chia-Ling Lee; Wei-Chun Huang; Jin-Shiou Yang; Cyuan-Fong Li; Chia-Hsin Chen; Ko-Long Lin
Journal:  Acta Cardiol Sin       Date:  2019-01       Impact factor: 2.672
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.